- By insider
CEO & President of Vertex Pharmaceuticals Inc (VRTX) Jeffrey M Leiden sold 125,000 shares of VRTX on 12/11/2017 at an average price of $141.35 a share. The total sale was $17.7 million.
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals Inc has a market cap of $35.83 billion; its shares were traded at around $141.68 with a P/E ratio of 181.62 and P/S ratio of 15.42.
-
Warning! GuruFocus has detected 1 Warning Sign with VRTX. Click here to check it out.
-
The intrinsic value of VRTX
CEO Recent Trades:
-
CEO & President Jeffrey M Leiden sold 125,000 shares of VRTX stock on 12/11/2017 at the average price of $141.35. The price of the stock has increased by 0.23% since.
Directors and Officers Recent Trades:
-
EVP, Global Research and CSO David Altshuler sold 306 shares of VRTX stock on 11/15/2017 at the average price of $149.12. The price of the stock has decreased by 4.99% since.
-
SVP & Corp Controller Paul M Silva sold 23 shares of VRTX stock on 11/15/2017 at the average price of $147.29. The price of the stock has decreased by 3.81% since.
-
EVP, COO Ian F Smith sold 7 shares of VRTX stock on 11/15/2017 at the average price of $147.29. The price of the stock has decreased by 3.81% since.
-
EVP, CRO Amit Sachdev sold 83 shares of VRTX stock on 11/15/2017 at the average price of $147.29. The price of the stock has decreased by 3.81% since.
-
EVPChief Commercial Officer Stuart A Arbuckle sold 221 shares of VRTX stock on 11/15/2017 at the average price of $147.29. The price of the stock has decreased by 3.81% since.
For the complete insider trading history of VRTX, click here
.This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 1 Warning Sign with VRTX. Click here to check it out.
-
The intrinsic value of VRTX